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Background: Previous studies reported conflicting results about the risk of developing glioma and different body
mass index. So we decided to execute a meta-analysis to solve the dispute.
Methods: Comprehensive literature retrieval was carried in PubMed, MEDLINE, and EMBASE up to September 15, 2014.
Hand literature information retrieval was not carried. Six studies were fit for this meta-analysis. Pooled hazard ratio (HR)
and 95 % confidence interval (CI) of different body mass index grade were performed by fixed/random-effects models,
except for normal weight which was referent.
Results: Data of 3726 cases were included. Compared with normal weight (20 kg.m−2 < body mass index
(BMI) ≤ 24.9 kg.m−2), the underweight (BMI ≤ 20 kg.m−2) might have lower incidence on the risk of developing
glioma (HR = 1.08, 95 % CI ranged 0.74 to 1.58, P = 0.678). While the overweight (25 kg.m−2 < BMI ≤ 29.9 kg.m−2)
and obesity (BMI ≥ 30 kg.m−2) were performed as a risk factor of developing glioma. The pooled HR of overweight
group was 1.12 (95 % CI ranged 1.02 to 1.22, P = 0.013); the pooled HR of obesity was 1.14 (95 % CI ranged 1.02
to 1.27, P = 0.017). Sensitivity analysis approved that our results were stable. There was no publication bias of
these studies.
Conclusions: Underweight could decrease the risk of developing glioma. Excess BMI was considered as a risk
factor to develop glioma.
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According to the diagnostic criteria of Tumours of the
Central Nervous System of 2007 version, gliomas are di-
vided into grade I~IV; grade III and IV tumors are consid-
ered malignant gliomas [1], which account for 30 %
primary CNS tumors [2]. Gliomas are considered as diffuse
infiltration of white matter tracts [3]. Compared with com-
mon magnetic resonance (MR) sequences which is insensi-
tivity for detecting the boundary of tumor [3, 4], MRS or/
and DTI is/are effective methods to distinguish the infiltra-
tion area of glioma [5]. There is a great progress in surgical
techniques and chemo-radiotherapy, but the median
survival time of patients is 12–15 months [6]. The patients’
5-year survival rate of WHO grade III glioma is 18 % and it
is <5 % for WHO grade IV tumors [7].* Correspondence: hqlxqyy@sina.com
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article, unless otherwise stated.Body mass index (BMI (kg.m−2)) was calculated as
weight (kg) divided by height (cm) squared and catego-
rized as underweight when BMI ≤ 20 kg.m−2, normal
weight when 20 kg.m−2 < BMI ≤ 24.9 kg.m−2, overweight
when 25 kg.m−2 < BMI ≤ 29.9 kg.m−2 and obesity when
BMI ≥ 30 kg.m−2 [8]. Previous studies have shown over-
weight and obese contributed to increase the fatalities
of endometrial cancer, colon cancer, and renal carcin-
oma [9]. But the relationships between developing gli-
oma and BMI are uncertain. Several recent studies
reported excess BMI was a predictor of glioma risk
[10, 11], whereas other studies did not show the similar
outcome [8, 12–14]. For solving this controversy, a
meta-analysis was carried out.Patients and methods
Literature retrieval and inclusive criteria
A literature search was executed in PubMed, MEDLINE,
and EMBASE from inception to September 15, 2014.s distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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follows: “body mass index”, “overweight”, “obesity” com-
bined with “glioma” which was a MeSH and limited in
“human”. Two reviewers independently sorted out eli-
gible trials according to the following inclusive criteria:
(I) a clear diagnosis of glioma; (II) underweight, over-
weight, or obesity defined by BMI; (III) relative risk (RR)
or hazard ratio (HR) with 95 % confidence interval (CI)
of BMI was reported; (IV) we included the most recent
and informative paper, if more than one article was
found on the same trial; (V) we excluded those studies
which were not fit for our inclusion criteria.
Data extraction and literature quality evaluation
Two reviewers (Z.F Dai and H.P Liu) independently sorted
out eligible trials according to inclusive criteria. Data ex-
traction was performed by two reviewers which included
the first author, year of publication, study design, country
of study, the number of male and female, median follow-
up, median age, HR, and 95 % CI (Table 1). Any disagree-
ments were resolved by discussion.
We used the Newcastle-Ottawa scale (NOS) to evaluate
the quality of papers. The NOS is an evaluation standard
of nonrandomized controlled trials composed with three
major parts: selection of the study groups (0–4 stars),
comparability of cases and controls (0–2 stars), or cohorts,
and ascertainment of exposure/outcome (0–3 stars). A
study was considered a high-quality research when its
NOS were equal or greater than 6 stars [15].
Statistical analysis
The pooled HRs and 95 % CIs were assessed to know the
correlation risk between glioma and underweight, over-
weight, or obesity. Greenland reported “if the outcome
under study is rare in all populations and subgroups underTable 1 Characteristics of the five trials included in meta-analysis
Author Year Design Country Male
Benson [10] 2008 Cohort
study
UK /




Wiedmann [8] 2013 Cohort
study
Norway 83
Michaud [14] 2011 Cohort
study
Cross-countrya 167
Jones [13] 2010 Cohort
study
USA 832
Moore [12] 2009 Cohort
study
USA 341
(aDenmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Swedenreview, one can generally ignore the distinctions among
the various measures of relative risk (e.g., odds ratios, rate
ratios, and risk ratios)” [16]. So we used this principle in
the study of Benson et al.: RRs were accurate approxima-
tions of HRs [10]. Statistical heterogeneity was quantified
with I2 statistic and Cochran’s Q with a significant level at
P < 0.1 [17]. Fixed-effects model was executed for sum-
mary data, if heterogeneity was not significant (I2 < 50 %).
While if I2 > 50 %, the random-effects model was selected
[17]. When I2 was less than 25 %, the heterogeneity was
low; When I2 was ranged 25 % from 50 %, the heterogen-
eity was moderate; and when I2 was more than 50 %, the
heterogeneity was high [18]. Sensitivity analysis was car-
ried to evaluate the effect of each inclusive study on the
results by excluding one study at a time. Sensitivity ana-
lysis was performed to evaluate the effect of each inclusive
study on the results by excluding one study at a time. Begg’s
test was performed to examine publication bias at two-side
test P value <0.05. All analyses were performed in STATA
12.0 version. All analyses were conducted in STATA 12.0
version. Screening article was based on preferred reporting
items for systematic reviews and meta-analyses (PRISMA)
statement (Review Manager Version 5.2 (Revman, the
Cochrane Collaboration, Oxford, England)) [19].Results
Characteristics of included trials and patients
With our search strategy, 450 trials were satisfied, and Fig. 1
shows a flow diagram for the selection process. After read-
ing the titles, 23 interesting articles were taken. After read-
ing the abstracts, seven papers were needed to get full text.
After reviewing the full-text, six trials met the inclusion
criteria and were included in meta-analysis [8, 10–14].
Two studies were performed in the USA [11–13],
and three trials in Europe [8, 10, 14]. Four studiesFemale Median
follow-up
(months)
Median age (years) NOS
646 74.4 57 ± 4.5 ******
347 12.4 57 ± 13.3 ******
65 282 48.1 (20–101) ******
173 100.8 / *******
427 40 58 ******
139 98.4 / ******
, and the United Kingdom)
Fig. 1 The PRISMA statement of meta-analysis
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cluded women only [10]. All included studies were of high
quality evaluated by NOS, which were equal to or more
than six stars. Detailed characteristics and NOS score of
the included studies are shown in Table 1.Fig. 2 Forest plots of meta-analysis results of underweight, overweight, anMeta-analysis
Six studies [8, 10–14] which contained 3726 patients were
included into meta-analysis. There was no significant
heterogeneity between these studies (I2 = 0.0 %, P = 0.912),
so the fixed-effects model of analysis was performed. Thed obesity, when normal weight was referent
Fig. 3 Sensitivity analysis for obesity
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1.20, P = 0.001) (Fig. 2), which mean excess BMI was a risk
factor to develop glioma.
Three studies [8, 11, 12, 14] provided the HR of
underweight. The heterogeneity was significant in
these studies (I2 = 0.0 %, P = 0.553), so random-effects
analysis was performed. The pooled HR of all studies
was 1.08 (95 % CI ranged 0.74 to 1.58, P = 0.678)
(Fig. 3), which mean underweight might decrease the
risk of suffering from glioma.
Six studies [8, 10–14] provided the HR of overweight
and obesity. There was no significant heterogeneity in
two groups (all I2 = 0.0 %), so fixed-effects analysis was
performed. The pooled HR of overweight group was
1.12 (95 % CI ranged 1.02 to 1.22, P = 0.013); the pooledFig. 4 Funnel plot for publication bias of obesityHR of obesity was 1.14 (95 % CI ranged 1.02 to 1.27,
P = 0.017) (Fig. 2). Excess BMI was considered as a risk
factor of developing glioma.Sensitive analysis
Sensitivity analysis was carried by excluding one study
at a time. There did not exist any one article that could
significantly influence the overall result stability indi-
vidually (Fig. 3).Publication bias
The outcomes of Egger’s test (t = 0.17, P = 0.873) and
symmetric funnel plot showed that there was no publi-
cation bias from these outcomes (Fig. 4).
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The meta-analysis showed the relationship of glioma
with underweight, overweight, and obesity compared
normal weight. Only three studies to date have analyzed
the relationship between the risk of glioma and under-
weight, and pooled HR of three studies show under-
weight could decrease the risk of developing glioma
[8, 11, 14]. Excess BMI (BMI ≥ 25 kg.m−2) was signifi-
cantly associated with a danger of developing glioma.
Many studies reported the overweight and obesity were
independent risk factors for poor outcome in patients
with glioma [8, 11–14]. At present, several potential the-
ories have been built to explain how obesity can influ-
ence the development of glioma. The most well-known
mechanism is the insulin-like growth factor (IGF) hy-
pothesis of obesity-related cancer, which has been impli-
cated in glioma proliferation and progression in vitro
[20–25]. A 22-case-control study showed a positive cor-
relation between serum IGF-1 levels and glioma risk
[26]. IGF-1 inhibitor was found effectively to suppress
growth of glioblastoma cell and induced tumor regres-
sion in vitro [27]. There is a peak level of IGF during
fetal brain development, and it decreases with age. But it
reappears in nervous tissue of glioma cells [28]. Insulin
resistance and hyperinsulinemia are very common
among excess body mass especially obesity [29], which
increase the level of free IGF. The free IGF can bind
insulin-like growth factor binding protein 1 (IGFBP-1)
and insulin-like growth factor binding protein 2 (IGFBP-
2). Correspondence with a decrease of the binding pro-
tein, more and more higher circulating concentrations of
free or bioactive insulin-like growth factor 1 (IGF-1),
was detected [21, 30].
Basing on our findings, we thought weight loss is
beneficial which may reduce insulin resistance in obese
patients. In addition, nutrients and phytochemicals in
fruit and vegetables might decrease glioma risk [31],
while socioeconomic level, daily alcohol intake, smoking
status, number of full-term pregnancies, age at first
birth, and oral contraceptive use were not significantly
associated with the incidence of glioma [10]. Moore
et al. found no link between weight gain between ages
18 and 50 years and glioma risk [12].
As we know, this is the first meta-analysis illustrating
the correlation of different BMI grades on the risk of gli-
oma. There are some advantages of this meta-analysis.
Firstly, meta-analysis can assess the consistency of result
and find the origin of heterogeneity. Secondly, meta-
analysis can evaluate and summarize results from differ-
ent studies which can increase the statistical efficiency
and accuracy. Thirdly, we could do detailed subgroup
analysis to identify risk factors relative to glioma.
Several potential limitations of this meta-analysis
should be noted. First, the number of included studieswas small which might let us underestimate the true as-
sociation. Second, as all included studies were observa-
tional, we cannot exclude all confounders like age,
region, and race. Third, because of our strict inclusive
criteria, many articles might exclude subject. Forth, the
data were not stratified according to the WHO grade of
tumors. Finally, unpublished negative results were needed
to be considered.
Conclusion
Underweight could decrease the risk of developing glioma.
Excess BMI was considered as a risk factor for developing
glioma. But this outcome needs more prospective studies
to further confirm the study.
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